Peter A. Olson
Chief Scientific OfficerDr. Peter A. Olson, also known as Pete, Ph.D., is Chief Scientific Officer of Iambic Therapeutics, Inc. from December 2024. He was vice president, research at Mirati Therapeutics. He is a specialist in cancer biology and genetics. At Mirati, he led in vitro and in vivo pharmacology and translational research across its portfolio, which included pre-clinical efforts for KRAZATI (adagrasib), a KRAS G12C inhibitor approved by the US Food and Drug Administration (FDA) in 2022. Dr. Olson has basic, pre-clinical and translational cancer biology experience in academia and industry and is the author of close to 50 peer-reviewed papers. Prior to Mirati he was a senior principal scientist in Pfizer’s Oncology Research Unit, where he was the translational project leader for OGSIVEO, the first FDA approved treatment for progressive desmoid tumors. Before Pfizer, he was a postdoc in the Hanahan Laboratory at the University of California, San Francisco. He received his Ph.D. in Biology from the University of California, San Diego and a B.S. in Biochemistry from the University of California, Davis.
Positions
- Company NameIambic Therapeutics, Inc.Stock CodeIAMPositionChief Scientific OfficerColleagues
- TMThomas MillerCo-Founder, CEO, Secretary & Director
- WHWilliam H. RastetterIndependent Chairperson
- FRFrederick R. ManbyCo-Founder, CTO & Director
- MSMichael SecoraChief Corporate Development Officer & CFO
- SCSunny ChangGeneral Counsel
- MTMary TagliaferriIndependent Director
- SSShalini SharpIndependent Director
